

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/222114 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 35/02 (2015.01)
C07D 417/14 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2021/029181

(22) International Filing Date:

26 April 2021 (26.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/016,760 28 April 2020 (28.04.2020) US

(71) Applicant: **RECURIUM IP HOLDINGS, LLC** [US/US];
10835 Road to the Cure, Suite 205, San Diego, California
92121 (US).

(72) Inventors: **PINCHMAN, Joseph, Robert**; 10835 Road to
the Cure, Suite 205, San Diego, California 92121 (US).
BUNKER, Kevin, Duane; 10835 Road to the Cure, Suite
205, San Diego, California 92121 (US). **HUANG, Peter**,

Qinhua; 10835 Road to the Cure, Suite 205, San Diego,
California 92121 (US).

(74) Agent: **MALLON, Joseph, J.**; Knobbe, Martens, Olson &
Bear, LLP, 2040 Main Street, 14th Floor, Irvine, California
92614 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: BCL-2 PROTEIN INHIBITORS





FIGURE 1



(57) Abstract: Various Bcl-2 protein inhibitors are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments the Bcl-2 protein inhibitors are compounds or pharmaceutically acceptable salts of the following Formula (I), where the variables in Formula (I) are defined herein. (I)

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))